Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.56 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.56 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751640 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| SCHEMBL1005841 | 0.86 | TSHR (0.55) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| SCHEMBL1996062 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| Hydrochloric Acid SCHEMBL28212666 | 0.84 | TSHR (0.53) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| Trifluoromethylbenzene SCHEMBL27691143 | 0.82 | ALDH1A1 (0.49) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| Hydrazine SCHEMBL28307217 | 0.82 | TSHR (0.52) | ALDH1A1TDP1TSHRCYP3A4HPGD | |
| SCHEMBL11732882 | 0.81 | HTT (0.47) | ALDH1A1TDP1TSHRHPGDCYP19A1 | |
| SCHEMBL16396157 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRCYP3A4CYP19A1 | |
| SCHEMBL204235 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TDP1TSHRCYP3A4CYP19A1 | |
| SCHEMBL1943699 | 0.79 | CYP19A1 (0.62) | ALDH1A1TDP1TSHRCYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115991873-A | Low-dielectric fluorinated aromatic polyimide film and preparation method thereof | 慧创(东莞)材料技术有限责任公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115991873-A | Low-dielectric fluorinated aromatic polyimide film and preparation method thereof | 慧创(东莞)材料技术有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-111909122-A | Diamine monomer containing 2, 5-furan dimethanol structure and preparation method thereof, polyimide film and preparation method thereof | 吉林大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-107108512-A | Therapeutic compound and application thereof | 基因泰克公司 | 2017-08-29 | — | — | CN | disclosed |
| US-8067582-B2 | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQIOBB COMPANY | 2010-12-30 | — | — | US | disclosed |
| EP-2170899-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687881-A | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO | 2010-03-31 | — | — | CN | disclosed |
| EP-1107964-B1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009003077-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | disclosed |
| US-5739133-A | N-ACYLATED AND ALKYLATED DERIVATIVES OF PYRIDAZINO(4,5-B)-QUINOLINES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS; STROKES; ANTIISCHEMIC AND HYPOGLYCEMIC AGENTS; PSYCHOSIS; NEUROGODEGENERATIVE DISORDERS | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5733910-A | Pyridazinedione compounds useful in the treating neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-03-31 | — | — | US | disclosed |
| US-5604227-A | EXCITATORY AMINO ACID ANTAGONIST; MONO, DI OR TRI-ACETYLATION OR ALKYLATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1997-02-18 | — | — | US | disclosed |
| US-5599814-A | SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-02-04 | — | — | US | disclosed |
| EP-0516297-B1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LTD (GB) | 1996-10-30 | — | — | EP | disclosed |
| EP-0516297-A1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | ALDH1A1 967/4885TDP1 4443/4885TSHR 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.